ALDX News and Press, Aldeyra Therapeutics Inc. From 09/18/23

2023-09-18 18:10:11 ET Summary Aldeyra Therapeutics' Q2 2023 report reveals a 52% cut in R&D spending, signaling a shift towards market readiness and commercial activities. The company maintains strong financial health with $151.7M cash reserves and a 40-month cash runway, red...

Investors who lost over $100,000 with Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) between March 2022 and June 2023 should contact the Shareholders Foundation in connection with Lawsuit PR Newswire SAN DIEGO , Aug. 22, 2023 /PRNewswire/ -- The Shareholders Foun...

SAN DIEGO, Aug. 15, 2023 (GLOBE NEWSWIRE) -- The Shareholders Foundation, Inc. announces that a lawsuit was filed for certain investors in Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) shares in effort to recover losses. Investors, who purchased shares in excess of $100,000 of Aldeyra Therapeutic...

NEW YORK, NY / ACCESSWIRE / August 8, 2023 / Levi & Korsinsky, LLP notifies investors in Aldeyra Therapeutics, Inc. ("Aldeyra" or the "Company") (NASDAQ:ALDX) of a class action securities lawsuit. The lawsuit on behalf of Aldeyra investors has been commenced in the United States District ...

2023-07-10 00:49:08 ET Summary Aldeyra Therapeutics reported $165 million in cash and cash equivalents as of March 31, 2023, with a net loss of $15.6 million for Q1 2023. The company's drug, reproxalap, is under FDA review for treating dry eye disease, with a decision expected in ...

2023-07-09 18:15:18 ET Acumen Pharmaceuticals ( NASDAQ: ABOS ), Establishment Labs ( NASDAQ: ESTA ), Arcus Biosciences ( NYSE: RCUS ) and BridgeBio Pharma ( NASDAQ: BBIO ) are four of BTIG's top picks for small and mid-cap healthcare stocks going into the lat...

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company developing innovative therapies for the treatment of immune-mediated diseases, today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, will participate in the SVB Securiti...

Best Corrected and Low‑Light Visual Acuity Statistically Significantly Improved As Assessed by Electroretinography, Time to Retinal Response Statistically Significantly Improved As Assessed by Macular and Dark-Adapted Perimetry, Retinal Sensitivity Statistically Significantly Impro...

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced it will host a webcast and conference call on Thursday, June 29, 2023, at 8:00 a.m. (ET) to provide top-line results from the Phase 2 clinical trial of ADX‑2191 in patients with retinitis pigmentosa. The dial-in numb...

Relative to Placebo, Statistical Significance Achieved for Reduction in Awake Cough Frequency (P=0.01), 24‑Hour Cough Frequency (P=0.001), Awake Cough Count (P=0.001), and 24‑Hour Cough Count (P=0.001) ADX-629 Was Well Tolerated and No Safety Concerns Were Identified ...